文献速递肝病

非酒精性脂肪性肝病(NAFLD)与非酒精性脂肪性肝炎(NASH)的全球流行病学:一项系统综述

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.
PubMed 文献 · Hepatology · 2023-01-03

该系统综述纳入1990至2019年调查年份的92项基于人群的研究(N=9,361,716),采用随机效应模型进行荟萃分析。全球NAFLD总体患病率为30.05%(95%CI:27.88%-32.32%),超声定义NAFLD患病率为30.69%(28.4-33.09),且随研究时期显著上升。拉丁美洲患病率最高(44.37%),非活检NAFLD队列全因死亡率为12.60/1000人年。

要点

  • 全球NAFLD总体患病率为30.05%(95%CI:27.88%-32.32%)。
  • 全球NAFLD患病率从1990-2006年的25.26%上升至2016-2019年的38.00%(p<0.001)。
  • 非活检NAFLD队列全因死亡率为12.60/1000人年(95%CI:6.68-23.67)。

核心结论

  • NAFLD全球患病率约为30%且呈上升趋势,需要在地方、区域和全球层面采取紧急综合策略以提高认知并应对NAFLD的各个方面。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Ovid MEDLINE中1990至2019年调查年份(最后发表于2022年)的NAFLD基于人群的研究,遵循PRISMA,采用随机效应模型,偏倚风险评估按Joanna Briggs Institute标准进行。
  • 共审查2585项研究,92项研究(N=9,361,716)符合纳入标准。

主要发现

  • 整个研究期间(1990-2019年),NAFLD患病率估计值的荟萃合并全球总体患病率为30.05%(95%CI:27.88%-32.32%),超声定义NAFLD的全球患病率为30.69%(28.4-33.09)。
  • 全球NAFLD患病率从1990-2006年的25.26%(21.59-29.33)上升至2016-2019年的38.00%(33.71-42.49),增加50.4%(p<0.001);超声定义NAFLD患病率从1990-2006年的25.16%(19.46-31.87)上升至34.59%(29.05-40.57),增加38.7%(p=0.029)。
  • NAFLD患病率最高的地区为拉丁美洲44.37%(30.66%-59.00%),其次为中东北非(36.53%,28.63%-45.22%)、南亚(33.83%,22.91%-46.79%)、东南亚(33.07%,18.99%-51.03%)、北美(31.20%,25.86%-37.08%)、东亚(29.71%,25.96%-33.76%)、亚太地区28.02%(24.69%-31.60%)、西欧25.10%(20.55%-30.28%)。
  • 在未通过肝活检诊断的NAFLD队列中,每1000人年的合并死亡率:全因死亡率为12.60(6.68-23.67),心脏特异性死亡率为4.20(1.34-7.05),肝外癌症特异性死亡率为2.83(0.78-4.88),肝脏特异性死亡率为0.92(0.00-2.21)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. APPROACH AND RESULTS: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Meta-analysis was conducted using random-effects models. Bias risk assessment was per Joanna Briggs Institute. Of 2585 studies reviewed, 92 studies (N=9,361,716) met eligibility criteria. Across the study period (1990-2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%-32.32%) and 30.69% (28.4-33.09), respectively. Global NAFLD prevalence increased by +50.4% from 25.26% (21.59-29.33) in 1990-2006 to 38.00% (33.71-42.49) in 2016-2019 ( p <0.001); ultrasound-defined NAFLD prevalence increased by +38.7% from 25.16% (19.46-31.87) in 1990-2006 to 34.59% (29.05-40.57) ( p =0.029). The highest NAFLD prevalence was in Latin America 44.37% (30.66%-59.00%), then Middle East and North Africa (MENA) (36.53%, 28.63%-45.22%), South Asia (33.83%, 22.91%-46.79%), South-East Asia (33.07%, 18.99%-51.03%), North America (31.20%, 25.86%-37.08%), East Asia (29.71%, 25.96%-33.76%), Asia Pacific 28.02% (24.69%-31.60%), Western Europe 25.10% (20.55%-30.28%). Among the NAFLD cohort diagnosed without a liver biopsy, pooled mortality rate per 1000 PY was 12.60 (6.68-23.67) for all-cause mortality; 4.20 (1.34-7.05) for cardiac-specific mortality; 2.83 (0.78-4.88) for extrahepatic cancer-specific mortality; and 0.92 (0.00-2.21) for liver-specific mortality. CONCLUSIONS: NAFLD global prevalence is 30% and increasing which requires urgent and comprehensive strategies to raise awareness and address all aspects of NAFLD on local, regional, and global levels.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023. PMID: 36626630. doi:10.1097/HEP.0000000000000004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。